Announcing the MESA INVITE Study!

MESA participants at Wake Forest, Columbia, Northwestern, and Johns Hopkins have the opportunity to participate in a new vitamin D treatment study: the Individualized response to Vitamin D Treatment (INVITE) study.

Vitamin D is important for good bone and general health. Your body can get vitamin D from sunlight, some foods, and treatment with supplements. Interestingly, people respond differently to vitamin D treatment. While some people experience large changes in their vitamin D levels, other people experience only small changes or no change at all. The purpose of this study is to figure out why people respond differently to vitamin D. We will test whether genes, hormones, or other biological factors might explain the variation in individual responses to vitamin D treatment.

As a MESA participant, you are eligible for this trial if you are not currently taking more than 1,000 units per day of vitamin D supplements and do not have a recent history of kidney stones. If you choose to participate, we will ask you to take a single pill every day for 16 weeks. The pills will contain either vitamin D or a placebo (a substance that looks the same but contains no vitamin D). You may continue to take your other medications and supplements, including low doses of vitamin D, throughout the study. We will ask you to return to the MESA examination center 16 weeks after Exam 6 to give a blood and urine sample, complete a short questionnaire, and return any extra study medication.

This trial is likely too short to directly benefit your health. However, the trial may help other people by allowing us to learn why individuals respond differently to vitamin D and improving our ability to treat vitamin D deficiency. We will provide you with your personal vitamin D levels measured at the beginning and end of the trial and will provide transportation, if needed, and monetary compensation for your time of $50.

To learn more about MESA INVITE, please contact your Field Center at the phone number in the MESA Messenger.

This study is funded by the National Heart, Lung, and Blood Institute (NHLBI) and is led by Drs. Ian de Boer and Bryan Kestenbaum at the University of Washington in Seattle.